Key Findings From Recent Trials

Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline.
• Brand Names Available In United States: Eldepryl (capsules 5 mg) and Zelapar (orally disintegrating tablets 1.25 mg).
• ATC Code: N04BD01 (Monoamine oxidase B inhibitors for anti‑parkinson drugs).
• Forms & Dosages: Tablets 5 mg and 10 mg; Capsules 5 mg; Orally disintegrating tablets (Zelapar) 1.25 mg; Transdermal patch (Emsam) 6, 9, 12 mg/24 hr.
• Manufacturers In United States: Somerset Pharmaceuticals (Eldepryl), Valeant (Zelapar), and generic suppliers such as Mylan.
• Registration Status In United States: Prescription only (Rx); approved by major regulatory agencies including FDA.
• OTC / Rx Classification: Prescription only (Rx) in most jurisdictions including the United States.

What do recent trials tell patients and prescribers about selegiline?

Across randomized and observational studies from 2022 to 2026, selegiline continued to show modest but consistent symptomatic benefit when used as an adjunct to levodopa in early‑to‑moderate Parkinson’s disease.

The clearest clinical gains reported were reductions in “off” time and a delay in the need for levodopa dose escalation.

Head‑to‑head pragmatic comparisons placed rasagiline and safinamide as close competitors in efficacy while highlighting differences in dosing and tolerability.

Most of the trial evidence concerns traditional oral formulations such as 5 mg capsules/tablets and 1.25 mg Zelapar ODTs.

Safety signals in the recent literature emphasized neuropsychiatric events, including hallucinations and insomnia, especially among elderly patients taking multiple CNS drugs.

Interactions with serotonergic and certain opioid drugs remained an important safety consideration reinforced by these trials.

Transdermal MAO strategies, notably Emsam patches used in depression, influenced trial designs but did not alter core recommendations for parkinsonian use.

Regulatory listings cited in trial reports align with selegiline’s Rx‑only status across major agencies.

Clinical Mechanism Of Action

Layman’s Explanation

What does selegiline do in plain terms?

Selegiline is an MAO‑B inhibitor that helps dopamine already present in the brain last longer.

That effect makes levodopa and the brain’s own dopamine work more effectively to reduce motor symptoms and reduce “off” periods.

Scientific Breakdown

At therapeutic oral doses, selegiline preferentially and irreversibly inhibits monoamine oxidase B (MAO‑B).

This inhibition raises synaptic dopamine and helps extend on‑time in people taking levodopa/carbidopa.

Selegiline is classified under ATC code N04BD01 for MAO‑B inhibitors used in Parkinson’s disease.

Oral metabolism can produce amphetamine‑like metabolites at higher doses, which helps explain stimulant‑type adverse effects such as insomnia and dry mouth.

Transdermal delivery (Emsam patch) bypasses first‑pass metabolism and changes metabolite exposure, creating a different tolerability profile compared with oral forms.

Enzyme Selectivity & Dopamine

Selegiline’s selectivity for MAO‑B at typical Parkinson’s doses helps avoid the full tyramine sensitivity seen with nonselective MAOIs.

However, the drug still carries interaction risks with serotonergic agents and certain opioids, which can lead to serotonin syndrome or hypertensive reactions.

Scope Of Approved And Off‑Label Use

United States Approvals

How is selegiline licensed and used in the United States?

Selegiline is approved as an adjunct antiparkinson agent and is prescription only.

Eldepryl capsules (5 mg) and Zelapar ODT (1.25 mg) are marketed in the United States.

The ATC classification remains N04BD01 for MAO‑B inhibitors used in Parkinson’s disease.

Transdermal selegiline (Emsam) is available in some markets for depression, but that indication and formulation are separate from Eldepryl marketed for Parkinson’s disease.

Notable Off‑Label Trends

Clinicians sometimes use low‑dose ODT formulations early in the disease course to smooth morning symptoms and delay levodopa dose escalation.

Transdermal formulations are occasionally considered when depressive symptoms coexist, although Emsam is the formulation approved for depression in some countries, not Eldepryl.

Off‑label use is constrained by contraindications and interaction risks, so prescribing patterns vary by clinician judgment and local availability.

Dosage Strategy

General Dosing

What are typical adult doses for Parkinson’s disease?

Standard dosing commonly ranges from 5 to 10 mg daily for oral tablets or capsules, often given as 5 mg twice daily.

Zelapar ODT is usually dosed at 1.25 mg once daily.

Transdermal patches (Emsam) are supplied as 6, 9, or 12 mg per 24 hours but are primarily indicated for depression in many markets.

Condition‑Specific Dosing

In early Parkinson’s, clinicians typically start at the lower end of the range and assess both motor benefit and tolerability.

Because selegiline is mainly an adjunct, conservative dosing is common to reduce interaction risk and stimulant adverse effects.

With Levodopa/Carbidopa

When selegiline is combined with levodopa/carbidopa, levodopa dose adjustment may be needed based on symptomatic response.

Monitor for increased dyskinesia and neuropsychiatric effects after starting or changing selegiline.

Pediatric dosing is not established and not recommended for children.

Elderly patients often start lower and are titrated carefully due to increased sensitivity and higher risk of adverse events.

Safety Protocols

Contraindications

Who should not take selegiline?

Absolute contraindications include known hypersensitivity to selegiline or any excipient.

Concurrent use with other MAOIs, certain opioid analgesics (for example, meperidine), and serotonergic agents is contraindicated because of severe interaction risks.

Pheochromocytoma is also an absolute contraindication because of the risk of hypertensive crisis.

Relative contraindications that demand close monitoring include peptic ulcer disease, severe cardiovascular disease, and psychotic or manic disorders.

Adverse Effects

Common mild to moderate side effects include nausea, dry mouth, dizziness, insomnia, headache, abdominal pain, and increased sweating.

Other notable effects are orthostatic hypotension, agitation, and hallucinations, which become more likely with polypharmacy and in older patients.

Monitoring Strategy

Perform a baseline medication reconciliation to screen for contraindicated drugs.

Check blood pressure if symptoms suggest a hypertensive reaction.

Monitor mental status for hallucinations or worsening psychosis, especially in elderly patients.

Review liver and kidney function as impaired clearance may require dose adjustments and closer follow‑up.

Educate patients on overdose risks and on when to seek urgent care for severe hypertension, seizures, or severe agitation.

Interaction Mapping

Food Interactions

Do patients need to avoid certain foods?

At typical MAO‑B‑selective doses, the risk of tyramine‑induced hypertensive crisis is lower than with nonselective MAOIs.

Nonetheless, patients should be cautious with tyramine‑rich foods such as aged cheeses and cured meats, especially if dosing changes or higher systemic MAO inhibition is suspected.

Drug Combinations To Avoid

Absolute contraindicated combinations include other MAOIs, meperidine and certain other opioids, and many serotonergic antidepressants due to the risk of serotonin syndrome or severe hypertensive reactions.

Certain sympathomimetics, antiemetics, and herbal supplements such as St. John’s wort require careful review before coadministration.

Management Of Interactions

Perform a thorough medication reconciliation and impose washout periods where clinically necessary and guideline supported.

Educate patients on warning signs such as severe headache, rapid blood pressure rise, hyperthermia, and altered mental status.

For unavoidable combinations, involve specialty consultation and plan close monitoring for early signs of serotonin syndrome or hypertensive events.

Patient Experience Analysis

Survey Data

What do patients report about selegiline in real life?

Survey data and clinic registries indicate patients often report modest improvements in morning stiffness and reductions in off time when selegiline is added to levodopa regimens.

Adherence can be affected by insomnia and stimulant‑like effects associated with oral metabolites.

ODT formulations are sometimes better tolerated for patients who experience oral stimulant effects or have trouble swallowing pills.

Forum Trends

Online forums mirror trial results: many users praise the drug for increased on‑time and delayed need for higher levodopa doses.

Frequent concerns raised include sleep disturbance, hallucinations in older adults, and out‑of‑pocket costs.

Some patients discuss switching to rasagiline or safinamide when insomnia or psychiatric side effects appear.

Clinicians should factor patient preference, sleep quality, and real‑world tolerability when choosing between MAO‑B inhibitors.

Distribution And Pricing Landscape

Market Suppliers

Which companies make selegiline and where is it sourced?

In the United States, Eldepryl is associated with Somerset Pharmaceuticals and Zelapar with Valeant, with generics supplied by companies such as Mylan.

Global manufacturers include Sun Pharma, Teva, Sandoz, Intas, and Abbott.

Formulations are packaged in blisters for tablets, capsules, ODTs, and patches where applicable.

Cost Drivers

Price variability is driven by brand versus generic status, formulation type, and payer coverage.

ODT and patch formats tend to cost more than standard tablets or capsules.

Supply chain factors and international generic availability can influence wholesale pricing in the United States.

In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

What are the main alternatives to selegiline for adjunctive management of Parkinson’s?

Key alternatives include rasagiline, safinamide, and COMT inhibitors such as entacapone and tolcapone.

Rasagiline offers once‑daily dosing and a favorable tolerability profile in many patients.

Safinamide provides reversible MAO‑B inhibition plus additional non‑dopaminergic effects that may help fluctuations.

COMT inhibitors work through a different mechanism to reduce wearing‑off when paired with levodopa.

Pros And Cons

• Selegiline: Pros — long clinical history and multiple formulations. Cons — oral metabolites can cause stimulant effects and insomnia, and interaction risks remain significant.
• Rasagiline: Pros — once‑daily dosing and potentially fewer metabolite‑related stimulant effects. Cons — similar interaction profile and cost/availability differences.
• Safinamide: Pros — reversible inhibition and adjunct benefit for motor fluctuations. Cons — newer agent and can be more expensive or less available.

Choice among these agents should weigh efficacy, side‑effect profile, dosing convenience, and formulary access.

Regulatory Status

Approvals & Classifications

How is selegiline classified internationally?

Selegiline is prescription only in most jurisdictions and is approved by major regulators including the FDA, EMA, and MHRA.

The ATC code N04BD01 classifies selegiline as a monoamine oxidase B inhibitor for antiparkinson therapy.

Form‑specific approvals vary by country, with Eldepryl and Zelapar approved in the United States and Emsam approved in some markets for depression.

Country‑Specific Notes

Manufacturer listings differ by market; in the UK, sovereign suppliers and blister pack presentations exist for 5 mg and 10 mg tablets.

National registries such as Romania’s ANMDMR include selegiline among anti‑parkinsonian medicines; always verify local product labeling and summaries of product characteristics for up‑to‑date information.

Consolidated FAQ

Top Clinical Questions

Is selegiline still used?

Yes. Selegiline remains an adjunct MAO‑B inhibitor used in Parkinson’s disease management, commonly at oral doses of 5–10 mg daily or 1.25 mg daily for Zelapar ODT.

Can it be combined with levodopa?

Yes. It is frequently used alongside levodopa/carbidopa to reduce wearing‑off, but monitoring for dyskinesia and psychiatric effects is essential.

What are absolute contraindications?

Concurrent MAOIs, certain opioids such as meperidine, serotonergic agents, pheochromocytoma, and known hypersensitivity are absolute contraindications.

Practical Patient Questions

What if I miss a dose?

Take the missed dose as soon as you remember unless it is nearly time for the next dose; do not double the dose.

How should I store it?

Store tablets, capsules, and ODTs in original packaging at room temperature below 25°C, away from moisture and light.

What if I overdose?

An overdose can cause severe hypertension, agitation, convulsions, or hallucinations and requires immediate medical attention.

Visual Guide

Formulation Icons

How can clinicians summarize formulations for patients quickly?

Use a simple matrix with rows for formulation types — tablet 5/10 mg, capsule 5 mg, ODT 1.25 mg, patch 6/9/12 mg/24 hr — and columns for typical uses such as early Parkinson’s, adjunct to levodopa, and depression for the patch form.

Icons like a pill, a dissolving tablet, and a transdermal patch reduce cognitive load during counseling.

Dosing Timeline

A horizontal timeline visually shows morning versus evening dosing and monitoring points.

Because oral metabolites can be stimulant‑like, morning administration is often favored to reduce insomnia.

Typical timelines include split dosing for 5 mg twice daily and single daily dosing for 1.25 mg ODT, with follow‑up checkpoints at 2–4 weeks for sleep and psychiatric symptoms and periodic blood pressure and liver/kidney checks.

Storage And Transport

Recommended Conditions

How should selegiline be stored and shipped?

Store selegiline formulations in original packaging at room temperature below 25°C, protected from moisture and light.

Tablets, capsules, and ODTs should not be refrigerated or frozen.

Transdermal patches have manufacturer‑specific guidance but are generally stored at controlled room temperature.

Handling Cautions

Keep all formulations out of reach of children and maintain blister integrity until use to protect against humidity.

For pharmacy distribution, avoid prolonged exposure to extremes of heat or cold that could compromise ODT integrity or patch adhesives.

Dispose of used patches safely because residual active drug remains in adhesive matrices.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers verify before initiating selegiline?

Confirm diagnosis and the indication for adjunctive MAO‑B therapy in Parkinson’s disease.

Reconcile all current medications to exclude contraindicated agents such as MAOIs, meperidine, and serotonergic drugs.

Choose the formulation based on symptom pattern and comorbidity — Eldepryl capsules/tablets or Zelapar ODT as appropriate.

Start at the lower end of dosing for elderly patients or those with hepatic impairment and plan a follow‑up visit to assess efficacy and adverse effects.

Patient Counseling Points

Explain simply that selegiline prolongs dopamine effects to reduce off time.

Warn about insomnia, nervousness, and the rare but serious signs of serotonin syndrome or hypertensive crisis.

Advise patients to check with their prescriber before starting new medications or herbal supplements.

Discuss cost considerations and brand versus generic options and remind patients that product storage should be below 25°C.

Delivery Across United States